Effect of Single Dose Intranasal Insulin On Cognitive Function

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Xiaoduo Fan, University of Massachusetts, Worcester
ClinicalTrials.gov Identifier:
NCT00646581
First received: January 31, 2008
Last updated: February 12, 2013
Last verified: February 2013
  Purpose

The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include:

  1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory.
  2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level

Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.


Condition Intervention Phase
Schizophrenia
Schizoaffective Disorder
Drug: Placebo
Drug: Insulin (Humulin)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by University of Massachusetts, Worcester:

Primary Outcome Measures:
  • Improvement in Cognitive Function- HVLT Immediate Recall Total (Number) [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed the HVLT Immediate Recall Task. For this task, participants were read aloud a list of 12 words from three taxonomic categories. Participants were read the list three separate times, and after each reading were immediately asked to recall as many words from the list as they could. The number of words recalled successfully was measured before and after intranasal treatment. Values below represent posttreatment performance minus pretreatment performance.

  • Improvement in Cognitive Function- HVLT-Delayed Recall (Number) [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed the HVLT word recall task after a 20-minute delay before and after intranasal treatment. In the HVLT delayed recall task, participants were asked to recall the same list of 12 words dictated in the immediate recall task 20 minutes after the completion of the immediate recall task. Words successfully recalled after the 20-minute delay were measured. Values below represent posttreatment performance minus pretreatment performance.

  • CPT d Score [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed a computer-based test designed to measure sustained attention (attention to a specific stimuli over a period of several minutes) before and after intranasal treatment. During this test, participants respond as quickly as possible to any consecutive presentation of identical stimuli on the computer screen. The stimuli (2, 3, and 4-digit targets) were presented with increasing cognitive load in successive blocks. Correct responses, responses made to the second of 2 identical stimuli presented in a row, were scored as hits. False alarms were also recorded. The "d prime score" is a score given to each participant on a scale of 0.0- 1.0 in which discrimination sensitivity is measured. A score of zero equates to no sensitivity, whereas a score of 1.0 equates to perfect sensitivity. Values below represent postreatment performance minus pretreatment performance.

  • Improvement in Cognitive Function- CPT Hits Rate (Proportion) [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed a computer-based test designed to measure sustained attention before and after intranasal treatment. The task is described in the previous outcome measure ("CPT d score"). Hits rate refers to each participant's ability to correctly respond to two consecutive target presentations (i.e. correct responses). Hits rate was measured as a proportion of overall attempts (0= no hits, 1.0= 100% accuracy on hits). Values below represent posttreatment performance minus pretreatment performance.

  • Improvement in Cognitive Function- CPT Reaction Time of Hits (Milliseconds) [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed a computer-based test designed to measure sustained attention before and after intranasal treatment. The task is described in detail in a previous outcome measure ("CPT d score"). Reaction time of hits refers to the average time each participant took to correctly respond to a stimuli in milliseconds. Values below represent posttreatment performance minus pretreatment performance.

  • Improvement in Cognitive Function- CPT False Alarm Rate (Proportion) [ Time Frame: pretreatment= in the morning; postreatment= in the afternoon, 30 minutes after intranasal spray administration ] [ Designated as safety issue: No ]
    Subjects performed a computer-based test designed to measure sustained attention before and after intranasal treatment. The task is described in detail in a previous outcome measure ("CPT d score"). False alarm rate refers to the proportion of overall attempts that were characterized as incorrect responses (responses to two non-identical targets). Values below represent posttreatment performance minus pretreatment performance.


Enrollment: 30
Study Start Date: October 2006
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo (1)
Subjects are given a one-time, single dose of placebo intranasal spray
Drug: Placebo
Placebo
Other Name: Placebo
Experimental: Single-Dose Intranasal Insulin
Subjects are given a one-time, single dose of intranasal insulin
Drug: Insulin (Humulin)
40 IU Intranasal Insulin will be administered once
Other Name: Humulin

Detailed Description:

Insulin signaling in the brain is associated with improved cognitive function in both animal and human studies. Intranasal administration of insulin, which is non-invasive and minimizes the risk of hypoglycemia, may represent a new intervention approach with the potential to improve cognition and real life functioning in this patient with schizophrenia.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-65 years
  • Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype
  • Male or female
  • Stable dose of the current antipsychotic drug for at least one month
  • Well established compliance with out-patient treatment per treating clinician's judgement.
  • Able to complete the cognitive assessment battery (must be English speaking)

Exclusion Criteria:

  • Inability to provide informed consent
  • Current substance abuse
  • On clozapine or olanzapine
  • Psychiatrically unstable per treating clinician's judgement.
  • Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases etc.
  • Incapable to complete the cognitive battery assessment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00646581

Locations
United States, Massachusetts
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
University of Massachusetts, Worcester
Investigators
Principal Investigator: Xiaoduo Fan, MD, MPH, MS UMass Medical School
  More Information

No publications provided

Responsible Party: Xiaoduo Fan, Principal Investigator, University of Massachusetts, Worcester
ClinicalTrials.gov Identifier: NCT00646581     History of Changes
Other Study ID Numbers: 4-2006, CORRC tracking number: 4-2006
Study First Received: January 31, 2008
Results First Received: August 17, 2012
Last Updated: February 12, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Massachusetts, Worcester:
Schizophrenia
Memory
Concentration
Insulin

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 23, 2014